Cosibelimab for CSCC in Patients With Kidney Transplant or Hematologic Malignancy
Dana-Farber Cancer Institute
Dana-Farber Cancer Institute
Dana-Farber Cancer Institute
M.D. Anderson Cancer Center
Zhejiang DTRM Biopharma
Dana-Farber Cancer Institute
OHSU Knight Cancer Institute
Emory University
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Novartis
Dana-Farber Cancer Institute
Gilead Sciences
Novartis
Novartis
AIO-Studien-gGmbH
Mayo Clinic
Mayo Clinic
Mayo Clinic
University of Cologne
Mayo Clinic
Mayo Clinic
M.D. Anderson Cancer Center
University of California, Davis
Dana-Farber Cancer Institute
National Cancer Centre, Singapore
Alliance for Clinical Trials in Oncology
Novartis
Boston Medical Center
Duke University
Novartis
Case Comprehensive Cancer Center
Swiss Cancer Institute
SWOG Cancer Research Network
Samsung Medical Center
M.D. Anderson Cancer Center
Massachusetts General Hospital
International Extranodal Lymphoma Study Group (IELSG)
City of Hope Medical Center
Technical University of Munich